Category Archives: Op-Ed

Seeing Beyond the Big Data Backlash

There has been a lot of talk lately that ‘Big Data’ is just BS. Peter Houston looks beyond the hype to reveal what companies should be focusing on. Do you remember the first time you heard the phrase ‘Big Data’? Chances are, unless data’s what you do, it was last year. Big Data became big […]
Also posted in E-Media, Global, Guest Blog, Marketing | Tagged , | 2 Comments

Clinical Trial Data Disclosure in Europe: EMA Biting Off More than It Can Chew?

Is the EMA biting off more than it can chew? Reflector The European Medicines Agency’s ambitions are huge – as befits a body with such huge responsibilities. But its capacities to achieve what it sets out to do are now falling ever shorter. The latest deficiency is revealed by its admission that it cannot meet […]
Also posted in Europe, Global, Guest Blog, R&D | Tagged , , , , | Leave a comment

Pharma Needs To Do More Than Attract Digital Talent

Pharma needs to do more than attract digital talent As digital becomes a greater part of the Pharma marketing mainstream, can the sector attract the digital marketing talent it needs to succeed in the space? That’s a question pondered this week by Rich Meyer on his World of DTC Marketing blog. Rich, ex-Eli Lilly, was […]
Also posted in E-Media, Europe, Global, Guest Blog, Marketing, multimedia, social media | Leave a comment

Twitter IPO Looks a Safe Bet for Pharma Marketers

A Twitter (TWTR) IPO is imminent and looks likely to cement the social network’s future – good news for pharma marketers that increasingly see the network as an important place to engage HCPs and the public. The world’s second favourite social networking platform is expected to list on the New York Stock Exchange sometime this […]
Also posted in E-Media, Global, Guest Blog, Marketing, multimedia, social media | Tagged , , , | Leave a comment

Pharma's Transparency Troubles

Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler It seems like open season on the pharmaceutical industry. Academics and consumer activists charge pharma companies with hiding clinical trial information on medical product safety, fueling […]
Also posted in Europe, FDA, Guest Blog, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta